Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC

ESMO 2024: Update on BRAF-altered lung cancer dataПодробнее

ADRIATIC from ESMO 2024 - Durvalumab as Consolidation in Limited-stage SCLC With Updates on PCIПодробнее

Highlights in lung cancer at ESMO 2023: PAPILLON and MARIPOSAПодробнее

Lung Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Joshua SabariПодробнее

Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung CancerПодробнее

MARIPOSA/MARIPOSA-2 ESMO 2024 - Importance of Amivantamab in mNSCLC Insights on Resistance PatternsПодробнее

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung CancerПодробнее

As the Gantry Turns, Updates from ESMO on the Adriatic TrialПодробнее

ESMO 2024: Highlights and analysisПодробнее

Colorectal cancer highlights at ESMO 2024: CheckMate 8HW and BREAKWATERПодробнее

Limited Stage Small Cell Lung Cancer: The Adriatic Study- 2024 Leading Developments in Lung CancerПодробнее

ESMO 2019 Daily Reporter - Editor's Picks: Lung cancerПодробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

ESMO 2024 - Henar Hevia & Carolyn SousaПодробнее